Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Effects of Pilates in Patients With Post- -COVID-19 Syndrome: Controlled and Randomized Clinical Trial

  • Read more about Effects of Pilates in Patients With Post- -COVID-19 Syndrome: Controlled and Randomized Clinical Trial

Fourth BNT162b2 COVID-19 Vaccine Dose

  • Read more about Fourth BNT162b2 COVID-19 Vaccine Dose

Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

  • Read more about Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

Exercise Intolerance in Post-COVID Patients

  • Read more about Exercise Intolerance in Post-COVID Patients

Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

  • Read more about Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

Shanghai Miracogen Inc.

By jpalfreyman on Fri, 12/01/2023 - 16:40
  • Read more about Shanghai Miracogen Inc.

Multidisciplinary Day-hospital Versus Waiting List Management of Post-COVID-19 Persistent Symptoms (ECHAP-COVID)

  • Read more about Multidisciplinary Day-hospital Versus Waiting List Management of Post-COVID-19 Persistent Symptoms (ECHAP-COVID)

Intermediate-Size Expanded Access Protocol (EAP) for LP352

  • Read more about Intermediate-Size Expanded Access Protocol (EAP) for LP352

Effectiveness and Safety of New Oral Antivirals for COVID-19

  • Read more about Effectiveness and Safety of New Oral Antivirals for COVID-19

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19

  • Read more about A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 104
  • Page 105
  • Page 106
  • Page 107
  • Current page 108
  • Page 109
  • Page 110
  • Page 111
  • Page 112
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA